Literature DB >> 18810578

Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation.

Manabu Horii1, Shiro Uemura, Masahito Uemura, Masanori Matsumoto, Hiromichi Ishizashi, Keiichi Imagawa, Hajime Iwama, Yukiji Takeda, Hiroyuki Kawata, Tamio Nakajima, Yoshihiro Fujimura, Yoshihiko Saito.   

Abstract

The aim of the present study is to clarify the roles of circulating ADAMTS13 and von Willebrand factor (VWF) in the formation of coronary artery thrombi in acute myocardial infarction (AMI). Twenty-six AMI patients, 37 age-matched healthy controls, and 20 young controls were studied. Plasma ADAMTS13 activity and levels of VWF antigen (VWF: Ag) and unusually large VWF multimer (UL-VWFM) were measured in the femoral vein (FV), aortic root (Ao), and coronary sinus (Cs) immediately before percutaneous coronary intervention (PCI) during the acute phase of AMI, as well as 6 months later. During the acute phase of AMI, plasma levels of VWF: Ag were similar in FV, Ao, and Cs, and were higher than those of age-matched control. In contrast, ADAMTS13 activity in three sampling points in AMI patients was similar to that of age-matched controls. Thus, the ratio of VWF: Ag to ADAMTS13 activity in the acute phase of AMI was significantly higher in all three sampled sites than that of age-matched controls. In the chronic phase, plasma levels of VWF: Ag, ADAMTS13 activity, and the ratio of VWF: Ag to ADAMTS13 activity were similar to those of age-matched controls. UL-VWFM was detected in the acute phase of AMI but not in the chronic phase. The present study showed that the plasma VWF: Ag levels are increased and ADAMTS13 activity is relatively decreased in both systemic and coronary circulation during the acute phase of AMI, suggesting that an imbalance between the enzyme and its substrate may play a role in the formation of occlusive thrombi in a coronary artery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810578     DOI: 10.1007/s00380-008-1053-x

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  20 in total

1.  Physical stress as a model to study variations in ADAMTS-13 activity, von Willebrand factor level and platelet activation.

Authors:  R A Claus; C L Bockmeyer; M Sossdorf; W Lösche; T Hilberg
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

Review 2.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

3.  Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction.

Authors:  K Kaikita; K Soejima; M Matsukawa; T Nakagaki; H Ogawa
Journal:  J Thromb Haemost       Date:  2006-08-08       Impact factor: 5.824

Review 4.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

5.  Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.

Authors:  Seiji Kato; Masanori Matsumoto; Tomomi Matsuyama; Ayami Isonishi; Hisahide Hiura; Yoshihiro Fujimura
Journal:  Transfusion       Date:  2006-08       Impact factor: 3.157

6.  Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Folsom; K K Wu; W D Rosamond; A R Sharrett; L E Chambless
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

7.  Localization of ADAMTS13 to the stellate cells of human liver.

Authors:  Masahito Uemura; Kouko Tatsumi; Masanori Matsumoto; Masao Fujimoto; Tomomi Matsuyama; Masatoshi Ishikawa; Taka-Aki Iwamoto; Toshio Mori; Akio Wanaka; Hiroshi Fukui; Yoshihiro Fujimura
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

Review 8.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.

Authors:  Morteza Naghavi; Peter Libby; Erling Falk; S Ward Casscells; Silvio Litovsky; John Rumberger; Juan Jose Badimon; Christodoulos Stefanadis; Pedro Moreno; Gerard Pasterkamp; Zahi Fayad; Peter H Stone; Sergio Waxman; Paolo Raggi; Mohammad Madjid; Alireza Zarrabi; Allen Burke; Chun Yuan; Peter J Fitzgerald; David S Siscovick; Chris L de Korte; Masanori Aikawa; K E Juhani Airaksinen; Gerd Assmann; Christoph R Becker; James H Chesebro; Andrew Farb; Zorina S Galis; Chris Jackson; Ik-Kyung Jang; Wolfgang Koenig; Robert A Lodder; Keith March; Jasenka Demirovic; Mohamad Navab; Silvia G Priori; Mark D Rekhter; Raymond Bahr; Scott M Grundy; Roxana Mehran; Antonio Colombo; Eric Boerwinkle; Christie Ballantyne; William Insull; Robert S Schwartz; Robert Vogel; Patrick W Serruys; Goran K Hansson; David P Faxon; Sanjay Kaul; Helmut Drexler; Philip Greenland; James E Muller; Renu Virmani; Paul M Ridker; Douglas P Zipes; Prediman K Shah; James T Willerson
Journal:  Circulation       Date:  2003-10-14       Impact factor: 29.690

9.  Intracoronary thrombus in nontransmural myocardial infarction and in unstable angina pectoris.

Authors:  J B Mandelkorn; N M Wolf; S Singh; J A Shechter; R I Kersh; D M Rodgers; M B Workman; L G Bentivoglio; S M LaPorte; S G Meister
Journal:  Am J Cardiol       Date:  1983-07       Impact factor: 2.778

10.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

Authors:  J H Jansson; T K Nilsson; O Johnson
Journal:  Br Heart J       Date:  1991-11
View more
  15 in total

1.  Antiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary study.

Authors:  Kenichi Fukushima; Yoshio Kobayashi; Hideki Kitahara; Yo Iwata; Nakabumi Kuroda; Masayuki Ooyama; Yoichi Kuwabara; Fumio Nomura; Issei Komuro
Journal:  Heart Vessels       Date:  2010-01-21       Impact factor: 2.037

2.  Different angiogenesis effect of mini-TyrRS/mini-TrpRS by systemic administration of modified siRNAs in rats with acute myocardial infarction.

Authors:  Rui Zeng; Yu-Cheng Chen; Zhi Zeng; Wei-Qiang Liu; Xiao-Xia Liu; Rui Liu; Ou Qiang; Xian Li
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

3.  Relative Deficiency of Plasma A Disintegrin and Metalloprotease with Thrombospondin Type 1 Repeats 13 Activity and Elevation of Human Neutrophil Peptides in Patients with Traumatic Brain Injury.

Authors:  Monisha A Kumar; Wenjing Cao; Huy P Pham; Dheeraj Raju; Kelsey Nawalinski; Eileen Maloney-Wilensky; James Schuster; X Long Zheng
Journal:  J Neurotrauma       Date:  2018-08-14       Impact factor: 5.269

4.  Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial.

Authors:  Igor Mrdovic; Lidija Savic; Ratko Lasica; Gordana Krljanac; Milika Asanin; Natasa Brdar; Nemanja Djuricic; Natasa Cvetinovic; Jelena Marinkovic; Jovan Perunicic
Journal:  Heart Vessels       Date:  2012-09-14       Impact factor: 2.037

5.  Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage.

Authors:  Monisha Kumar; Wenjing Cao; Jenny K McDaniel; Huy P Pham; Dheeraj Raju; Kelsey Nawalinski; Suzanne Frangos; David Kung; Eric Zager; Scott E Kasner; Joshua M Levine; X Long Zheng
Journal:  Thromb Haemost       Date:  2017-01-19       Impact factor: 5.249

6.  Effect of mini-tyrosyl-tRNA synthetase/mini-tryptophanyl-tRNA synthetase on ischemic angiogenesis in rats: proliferation and migration of endothelial cells.

Authors:  Rui Zeng; Yu-cheng Chen; Zhi Zeng; Wei-qiang Liu; Xiao-fei Jiang; Rui Liu; Ou Qiang; Xian Li
Journal:  Heart Vessels       Date:  2010-10-21       Impact factor: 2.037

7.  Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.

Authors:  Simon F De Meyer; Alexander S Savchenko; Michael S Haas; Daphne Schatzberg; Michael C Carroll; Alexandra Schiviz; Barbara Dietrich; Hanspeter Rottensteiner; Friedrich Scheiflinger; Denisa D Wagner
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

8.  ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice.

Authors:  Chintan Gandhi; David G Motto; Melissa Jensen; Steven R Lentz; Anil K Chauhan
Journal:  Blood       Date:  2012-09-14       Impact factor: 22.113

Review 9.  COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.

Authors:  Jae C Chang
Journal:  Vasc Health Risk Manag       Date:  2021-06-01

10.  Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study.

Authors:  Mehmet Kayrak; Ahmet Bacaksiz; Mehmet S Ulgen; Mehmet Akif Vatankulu; Kadriye Zengin; Selim S Ayhan; Mustafa Kemal Basaralı; Sadik Büyükbas; Aysel Kiyici
Journal:  Heart Vessels       Date:  2010-10-27       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.